Close Menu

Biocept

The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

NEW YORK (GenomeWeb) – Biocept reported today that its third quarter net loss increased 34 percent year over year, as the firm expanded initiatives in its fledgling oncology diagnostics business.

NEW YORK (GenomeWeb) — Biocept and Rosetta Genomics said this week that they will pair Biocept's circulating tumor cell isolation technology with Rosetta's microRNA analysis platforms to investigate the possibility of developing blood-based cancer diagnostics and therapeutic response assays.

NEW YORK (GenomeWeb) — Biocept and Rosetta Genomics said today that they will collaborate in the area of cancer diagnostics.

NEW YORK (GenomeWeb) — Biocept said today that it has expanded its collaboration with the University of Texas MD Anderson Cancer Center in the area of ovarian cancer.

NEW YORK (GenomeWeb) — Diagnologix, a year-old startup developing microbubble-based sample prep technology, has been awarded a $25,000 grant as part of the company's acceptance into I-Corps, a recently established business-development program from the National Institutes of Health and National Sc

This article has been updated from a previous version to more accurately characterize cell-free DNA (cfDNA) as circulating tumor DNA (ctDNA).

NEW YORK (GenomeWeb) – Biocept today reported a 60 percent drop in its second quarter revenues.

Asuragen said this week that it has appointed Matthew McManus as CEO and president.

Biocept announced the hiring of Amy McNeal as its new senior director of managed care and reimbursement strategies. Biocept is a molecular diagnostics firm specializing in analysis of biomarkers from circulating tumor cells and DNA.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.